Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure

Virology Journal

Volumn 10, Issue , 2013, Pages

  Weng, Min ^a   Zeng, Wei Zheng ^a   Wu, Xiao Ling ^a   Zhang, Yong ^a   Jiang, Ming De ^a   Wang, Zhao ^a   Zhou, De Jiang ^a   He, Xuan ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Chronic hepatitis B; Hepatitis B surface antigen quantification; Lamivudine exposure; Pegylated interferon 2a; Predictability

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA VIRUS; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MALE; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SEROCONVERSION;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883532800     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-277     Document Type: Article

References (12)

1. Viral hepatitis B. Lai CL, Ratziu V, Yuen MF, Poynard T, Lancet 2003 362 2089 2094 10.1016/S0140-6736(03)15108-2 14697813
2. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, et al. J Hepatol 2013 58 427 433 10.1016/j.jhep.2012.10.025 23123221
3. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF, Clin Gastroenterol Hepatol 2013 11 1004 1010 10.1016/j.cgh.2013.01.026 23376799
4. Kinetics of intrahepatic cccDNA and serum HBsAg during antiviral therapy for chronic hepatitis B-lessons from experimental and clinical studies. Zoulim F, Testoni B, Lebosse F, Clin Gastroenterol Hepatol 2013 11 1011 1013 10.1016/j.cgh.2013.04.010 23602824
5. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? Lampertico P, Vigano M, Colombo M, Liver Int 2013 33 Suppl 1 157 163 23286860
6. Chronic hepatitis B. Lok AS, McMahon BJ, Hepatology 2007 45 507 539 10.1002/hep.21513 17256718
7. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. Cheng PN, Liu WC, Tsai HW, Wu IC, Chang TT, Young KC, J Med Virol 2011 83 602 607 10.1002/jmv.22014 21328373
8. Hepatitis B surface antigen quantification: not what it seems on the surface. Locarnini S, Bowden S, Hepatology 2012 56 411 414 10.1002/hep.25732 22454331
9. Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Vigano M, Lampertico P, Saudi J Gastroenterol 2012 18 81 86 10.4103/1319-3767.93805 22421711
10. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment. Chen EQ, Wang TT, Bai L, Tao CM, Liang T, Liu C, Liao J, Tang H, Antivir Ther 2013 doi:10.3851/IMP2579 [Epub ahead of print]
11. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study. Gheorghita VI, Caruntu FA, Curescu M, Olaru I, Radu MN, Coltan G, Streinu-Cercel A, J Gastrointestin Liver Dis 2013 22 27 32 23539387
12. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Peng CY, Lai HC, Li YF, Su WP, Chuang PH, Kao JT, Aliment Pharmacol Ther 2012 35 458 468 10.1111/j.1365-2036.2011.04973.x 22225574